Watson James Dean
SEC insider (Form 3/4/5 filer). CIK 0002130384. Director at Scribe Therapeutics, Inc. (SCTX). 1 reported Form 4/5 transaction since Sep 2024; latest on Jul 23, 2026. Located in ALAMEDA, CA.
Companies Watson James Dean has filed insider reports for
- Scribe Therapeutics, Inc. (SCTX): Director
Watson James Dean
CIK: 0002130384
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
SCTX
Scribe Therapeutics, Inc.
Director